COVID-19 in patients with systemic lupus erythematosus: A systematic review.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0962 (Electronic) Linking ISSN: 09612033 NLM ISO Abbreviation: Lupus Subsets: MEDLINE
    • Publication Information:
      Publication: London : SAGE Publications
      Original Publication: Houndmills, Basingstoke, Hampshire, UK : Scientific & Medical Division, Macmillan Press Ltd., c1991-
    • Subject Terms:
    • Abstract:
      The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.
    • References:
      Drugs Context. 2020 Jul 20;9:. (PMID: 32742294)
      J Clin Rheumatol. 2020 Sep;26(6):234-235. (PMID: 32826658)
      Transl Psychiatry. 2021 Jul 9;11(1):384. (PMID: 34244469)
      Ann Rheum Dis. 2021 Apr;80(4):e52. (PMID: 32616604)
      Ann Rheum Dis. 2021 May;80(5):e69. (PMID: 32737111)
      ACR Open Rheumatol. 2019 Oct 18;1(9):593-599. (PMID: 31777844)
      Case Rep Rheumatol. 2020 Nov 12;2020:8860492. (PMID: 33224548)
      Open Access Rheumatol. 2020 Sep 22;12:215-222. (PMID: 33061689)
      Ann Rheum Dis. 2021 Feb;80(2):e25. (PMID: 32451344)
      Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
      Clin Rheumatol. 2020 Sep;39(9):2803-2810. (PMID: 32725351)
      Acta Med Indones. 2020 Jul;52(3):214-226. (PMID: 33020333)
      Ann Rheum Dis. 2021 Feb;80(2):1-2. (PMID: 32586918)
      Br J Clin Pharmacol. 2021 Mar;87(3):1432-1442. (PMID: 32964535)
      JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899)
      J Rheumatol. 2020 Jun 1;47(6):787-790. (PMID: 32269064)
      Arthritis Rheumatol. 2020 Dec;72(12):1971-1980. (PMID: 32715660)
      J Med Virol. 2021 Feb;93(2):1184-1187. (PMID: 32926434)
      Ann Rheum Dis. 2021 May;80(5):e77. (PMID: 32759254)
      Eur J Dermatol. 2020 Dec 1;30(6):751-753. (PMID: 33289491)
      Rheumatol Int. 2021 Aug;41(8):1457-1464. (PMID: 34089358)
      J Rheumatol. 2021 Apr;48(4):603-607. (PMID: 33191284)
      J Med Case Rep. 2021 Jan 25;15(1):29. (PMID: 33494816)
      Lancet Rheumatol. 2021 Jan;3(1):e19-e27. (PMID: 33349815)
      Disaster Med Public Health Prep. 2021 Aug;15(4):e12-e15. (PMID: 32907688)
      Ann Rheum Dis. 2020 Oct;79(10):1382-1383. (PMID: 32398281)
      Ann Rheum Dis. 2021 Apr;80(4):e56. (PMID: 32513650)
      Ann Rheum Dis. 2021 Jun;80(6):e94. (PMID: 32586921)
      Rheumatol Int. 2020 Oct;40(10):1593-1598. (PMID: 32794113)
      Int J Rheum Dis. 2020 Aug;23(9):1255-1257. (PMID: 32841510)
      Respir Med Case Rep. 2020;31:101252. (PMID: 33078093)
      J Clin Med. 2020 Sep 05;9(9):. (PMID: 32899470)
      Gerontology. 2021;67(3):255-266. (PMID: 33406518)
      J Autoimmun. 2020 Aug;112:102502. (PMID: 32527675)
      Front Immunol. 2020 Oct 30;11:589474. (PMID: 33193418)
      Nat Rev Rheumatol. 2009 Jul;5(7):400-4. (PMID: 19506585)
      Lupus Sci Med. 2021 Apr;8(1):. (PMID: 33875571)
      PLoS Med. 2020 Jul 21;17(7):e1003166. (PMID: 32692736)
      Rheumatol Int. 2021 Apr;41(4):799-809. (PMID: 33543338)
      Adv Rheumatol. 2021 Jul 2;61(1):43. (PMID: 34215349)
      Ann Intern Med. 2020 Jun 2;172(11):754-755. (PMID: 32232419)
      Psychol Med. 2021 Apr;51(6):881-893. (PMID: 33648613)
      Clin Immunol. 2020 May;214:108413. (PMID: 32276139)
      Ann Rheum Dis. 2021 Mar;80(3):e35. (PMID: 32475835)
      Joint Bone Spine. 2020 Oct;87(5):495. (PMID: 32534206)
      Ann Rheum Dis. 2020 Sep;79(9):1170-1173. (PMID: 32532753)
      Lupus. 2021 Apr;30(5):836-839. (PMID: 33509065)
      J Clin Rheumatol. 2021 Mar 1;27(2):e60-e61. (PMID: 32947435)
      Ann Rheum Dis. 2020 Dec;79(12):1544-1549. (PMID: 32796045)
      Ann Rheum Dis. 2020 Jun;79(6):837-839. (PMID: 32332072)
      PLoS One. 2021 Jan 13;16(1):e0245274. (PMID: 33439910)
      Am J Case Rep. 2020 Sep 26;21:e927304. (PMID: 32978364)
      Clin Rheumatol. 2020 Sep;39(9):2811-2815. (PMID: 32720260)
      Ann Rheum Dis. 2022 Aug;81(8):e144. (PMID: 32788397)
      Open Med (Wars). 2020 Oct 14;15(1):1054-1060. (PMID: 33336061)
      Lupus. 2021 Jan;30(1):172-174. (PMID: 33092468)
      BMJ. 2009 Jul 21;339:b2535. (PMID: 19622551)
      Lupus. 2021 Jan;30(1):158-164. (PMID: 33019877)
      Ann Rheum Dis. 2020 Jul;79(7):859-866. (PMID: 32471903)
      Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9695-9697. (PMID: 33015814)
      Semin Arthritis Rheum. 2020 Oct;50(5):1150-1157. (PMID: 32927376)
      Clin Microbiol Infect. 2021 Apr;27(4):611-617. (PMID: 33316402)
      Lupus. 2020 Nov;29(13):1661-1672. (PMID: 33059530)
      Rev Med Virol. 2022 Mar;32(2):e2276. (PMID: 34245622)
      Clin Microbiol Infect. 2021 Apr;27(4):532-537. (PMID: 33476807)
      Lancet Rheumatol. 2020 Aug;2(8):e452-e454. (PMID: 32835249)
      N Engl J Med. 1991 Jan 17;324(3):150-4. (PMID: 1984192)
      Arthritis Care Res (Hoboken). 2021 May 31;:. (PMID: 34057311)
      RMD Open. 2021 Jan;7(1):. (PMID: 33510041)
      Curr Opin Psychiatry. 2021 Sep 1;34(5):477-484. (PMID: 34310357)
      Ann Rheum Dis. 2020 Nov;79(11):1393-1399. (PMID: 32769150)
      Epidemiol Infect. 2021 Jan 14;149:e24. (PMID: 33441205)
    • Contributed Indexing:
      Keywords: COVID-19; SARS-CoV-2; SLE; Systematic Review
    • Accession Number:
      4QWG6N8QKH (Hydroxychloroquine)
    • Publication Date:
      Date Created: 20220406 Date Completed: 20220426 Latest Revision: 20220716
    • Publication Date:
      20221213
    • Accession Number:
      PMC8990101
    • Accession Number:
      10.1177/09612033221093502
    • Accession Number:
      35382637